Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: Breast Neoplasms trials

The registry lists 94 Breast Neoplasms studies with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor. 58 are open to participants now and 0 have results posted.

Phase 1 8Phase 2 28Phase 3 15Phase 4 2No phase 45(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingNCT07892274Phase 3
• Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast CancerNot yet recruitingNCT07880106
• Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast CancerRecruitingNCT07796880Phase 2
• Research on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language ModelsNot yet recruitingNCT07767565
• Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of CINV in Breast Cancer Patients Receiving Highly Emetogenic ChemotherapyNot yet recruitingNCT07761325Phase 3
• A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingNCT07618390Phase 2
• Ultrasound Monitoring of Clipped Lymph Nodes to Predict Axillary Response After Chemotherapy in Breast CancerNot yet recruitingNCT07596472
• A Single-Center, Retrospective Study to Improve the Visibility of Breast Tissue Marker Clips in Breast Tissue and Axillary Lymph Nodes Using the Color Doppler Twinkling ArtifactNot yet recruitingNCT07554781
• Endoscopic Skin-Sparing vs. Conventional Mastectomy for Wound Complications in BCRecruitingNCT07548762Not applicable
• Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled StudyNot yet recruitingNCT07533526Not applicable
• Large Language Models Assist in Tumor MDTRecruitingNCT07504367Not applicable
• Pedicled Lateral Chest Wall Lymph-Adipofascial Flap to Prevent Arm Lymphedema After Breast Cancer SurgeryNot yet recruitingNCT07415200Not applicable
• Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast CancerRecruitingNCT07401537Phase 2
• Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT07400523Phase 3
• Acupuncture and Compression for the Prevention of CIPN in Breast Cancer PatientsRecruitingNCT07377279Not applicable
• Regional Radiotherapy Omission in Low-Risk Node Positive Breast CancerRecruitingNCT07179744
• Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerRecruitingNCT07095023Not applicable
• Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast CancerRecruitingNCT07066280Phase 3
• Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast CancerRecruitingNCT07037199Phase 2
• Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant TherapyRecruitingNCT06992336Phase 2
• Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer PatientsRecruitingNCT06892093Not applicable
• Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingNCT06889688Phase 3
• The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.RecruitingNCT06851299Phase 2
• The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast CancerRecruitingNCT06641544Phase 4
• A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBCNot yet recruitingNCT06632405Phase 2
• Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid TumorNot yet recruitingNCT06551896Phase 2
• A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast CancerNot yet recruitingNCT06530082Phase 1
• An AI Model Predicts the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: a Multicenter, Bidirectional Cohort StudyEnrolling by invitationNCT06510127
• Aromatherapy in the Treatment of Early Breast CancerNot yet recruitingNCT06435104Phase 2
• The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast SurgeryRecruitingNCT06425874
• HCQ+ADC vs ADC in the Treatment of Advanced Breast CancerRecruitingNCT06328387Phase 1/2
• Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast ReconstructionRecruitingNCT06319157Not applicable
• AMH Predicts Postchemotherapy Menopause in Premenopausal Breast Cancer PatientsNot yet recruitingNCT06313476
• Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant ChemoterapyRecruitingNCT06313463Phase 3
• AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes TumorsRecruitingNCT06286267
• Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialRecruitingNCT06278870Phase 3
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingNCT06121570Phase 1
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingNCT06121557Phase 1
• Diagnostic Biomarkers Exploration of Breast Cancer From Serum and UrineRecruitingNCT06102018
• Cold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled TrialRecruitingNCT06024187Not applicable
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingNCT05981014Phase 1/2
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingNCT05981001Phase 1/2
• A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BCRecruitingNCT05945368Phase 2
• Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)RecruitingNCT05904964Phase 3
• The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBCNot yet recruitingNCT05862610Phase 2
• Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neoadjuvant TherapyRecruitingNCT05838001Not applicable
• Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World StudyNot yet recruitingNCT05801705
• Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast CancerRecruitingNCT05797454Not applicable
• Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabRecruitingNCT05760612Phase 3
• A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILsRecruitingNCT05556200Phase 2
• Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast CancerRecruitingNCT05159193Phase 3
• Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast CancerRecruitingNCT04646759Phase 3
• A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBCRecruitingNCT04501523Phase 2
• RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast CancerRecruitingNCT04069884Not applicable
• Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast CancerRecruitingNCT04023292Phase 2
• MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)RecruitingNCT04004559
• Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast CancerRecruitingNCT03260192
• Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer PatientsRecruitingNCT02062489Phase 3
• Research on the Development and Validation of Personalized Exercise Prescriptions for Breast Cancer Patients Based on Large Language ModelsActive, not recruitingNCT07619781
• Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast CancerActive, not recruitingNCT07371910Phase 3
• Effects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 ResectionCompletedNCT06780059
• Deep Learning With MRI-based Multimodal-data Fusion Enhanced Postoperative Risk Stratification of Breast CancerCompletedNCT06546072
• Endoscopic Extirpation of Benign Breast Tumors Using a Lateral Chest Wall IncisionCompletedNCT06472700
• Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast CancerActive, not recruitingNCT06144944Phase 3
• PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast CancerCompletedNCT05812326Phase 1/2
• Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple DischargeCompletedNCT05812040Not applicable
• Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast CancerActive, not recruitingNCT05466786
• Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast CancerActive, not recruitingNCT05463601Phase 2
• Study on the Correlation Between the Quantitative Parameters of Mr Mean Cell Size Imaging and the Histopathological Characteristics of Breast CancerStatus unknownNCT05373628Not applicable
• Biomarkers of Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer PatientsStatus unknownNCT05181202
• Aesthetic Outcomes of Oncoplastic Breast Surgery for Breast Cancer in the Upper Inner QuadrantStatus unknownNCT05179304Not applicable
• Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label TrialActive, not recruitingNCT05165225Phase 2
• The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot SyndromeActive, not recruitingNCT05165069Phase 3
• Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast CancerStatus unknownNCT04891731
• Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast CancerActive, not recruitingNCT04872985Phase 2
• Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast CancerStatus unknownNCT04683770
• Efficacy and Safety of Eribulin in the Treatment of Advanced Breast CancerStatus unknownNCT04683445
• Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast CancerStatus unknownNCT04681911Phase 2
• Type I Interferon Alfa-2a in Postmastectomy Breast ReconstructionCompletedNCT04522557Phase 1
• Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer PatientsStatus unknownNCT04456855
• A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBCStatus unknownNCT04303741Phase 2
• Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line ChemotherapyCompletedNCT04258163
• KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast CancerStatus unknownNCT04034823Phase 2
• Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast CancerStatus unknownNCT04034589Phase 2
• Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01)Status unknownNCT04003558
• A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBCCompletedNCT03394287Phase 2
• Predict the Risk of Axillary Metastases in Breast Cancer Patients With Axillary UltrasoundStatus unknownNCT02992769
• Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer PatientsStatus unknownNCT02982148Phase 4
• Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast CancerSuspendedNCT02897050Phase 2
• A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast CancerCompletedNCT02742051Phase 2
• microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With HerceptinStatus unknownNCT02656589
• Cavity Shaving in Breast Conserving Surgery for Breast Cancer PatientsCompletedNCT02648802Not applicable
• Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer PatientsWithdrawnNCT02376413
• Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer PatientsStatus unknownNCT01503905Not applicable